Each month, The Clinical Advisor makes one new clinical feature available ahead of print. Don’t forget to take the poll. The results will be published in the next month’s issue. The American Heart ...
Heart failure sounds alarming—and rightfully so. Yet approximately 6.5 million Americans currently live with this condition, many with the specific variant called systolic heart failure, and a ...
Living with a heart that struggles to pump effectively creates daily challenges for millions of Americans. Systolic heart failure fundamentally changes how patients experience everyday activities.
Chicago, IL - Prolongation of the QRS interval, an electrocardiographic marker for ventricular dyssynchrony, is present in more than a third of low-LVEF patients hospitalized for acute heart failure ...
The heart is a muscle like no other, beating 60 to 100 times per minute on average, around the clock. But when it grows weak, it can lead to serious problems: from debilitating shortness of breath and ...
TipRanks on MSN
Seastar Medical’s Innovative Approach to Treating Severe Heart Failure: A Study Update
Seastar Medical Holding Corporation (($ICU)) announced an update on their ongoing clinical study. Seastar Medical Holding Corporation (ICU) is ...
It is a common perception that approximately 50% of heart failure (HF) patients present with a normal or near-normal left ventricular (LV) ejection fraction ("HF with preserved systolic function"), ...
Peripartum cardiomyopathy (PPCM) is a rare but life-threatening condition that can affect women with previously healthy ...
The Phase 2b SEISMiC Extension Study showed istaroxime significantly improved systolic blood pressure over six hours compared to placebo. Windtree plans to present detailed study findings, including ...
Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin‐converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the ...
On Wednesday, Windtree Therapeutics, Inc. (NASDAQ:WINT) released topline results from its Phase 2b SEISMiC Extension Study of istaroxime for patients in early cardiogenic shock due to heart failure.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results